deltatrials
Unknown OBSERVATIONAL NCT05009017

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

The Safety Study of Bevacizumab Biosimilars in the Real World

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Conditions Biosimilar
Interventions Bevacizumab
Updated 4 times since 2021 Last updated: Aug 12, 2021 Started: Jan 1, 2021 Primary completion: Jul 31, 2022 Completion: Dec 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Biosimilar, this trial is ongoing. The trial is conducted by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2021 – ~Sep 2023 · 24 months · monthly snapshotRecruiting~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 21 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  3. Sep 2023 — Jul 2024 [monthly]

    Unknown Status

    Status: Recruiting → Unknown Status

  4. Sep 2021 — Sep 2023 [monthly]

    Recruiting

    First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations